Latest rheumatoid arthritis drugs compared
RA is a chronic, debilitating, inflammatory disease of the joints, which is usually treated with anti-inflammatory drugs such as methotrexate or steroids. However, the discovery that a protein from white blood cells, known as tumour necrosis factor alpha (TNFa), caused some of the symptoms of RA, led to the development of novel drugs which block TNFa. This group of drugs, known as anti-TNFa drugs (which include infliximab, etanercept and adalimumab), are now commonly used to treat RA.
However, there have been no 'head-to-head' comparisons of the new anti-TNFa drugs in terms of safety or efficacy for the treatment of RA.
Alberto Alonso-Ruiz of the Cruces Hospital in Barakaldo, Vizcaya, Spain and colleagues at the Donostia Hospital and the University of the Basque Country, systematically searched for research on the use of anti-TNFa drugs in RA patients. They found thirteen clinical trials including over 7000 patients. The researchers then analyzed the trial results, systematically logging patient benefits and side effects for different doses of the three main anti-TNFa drugs.
Analysis of the combined results of all thirteen trials showed that anti-TNFa drugs, given at recommended doses, were better than the usual treatments, such as methotrexate, for treating RA. Patients who had previously seen little benefit from methotrexate alone showed a better response with combined anti-TNFa plus methotrexate therapy.
The team found that all three drugs were very similar in their benefits even at doses higher than those recommended by the drug manufacturer. This class of drugs, while very effective, does have a higher frequency of adverse side-effects. Patients on infliximab were most likely to drop out of a trial because of these side effects. In contrast, patients using etanercept had the lowest withdrawal rate. The researchers point out that this could be because this drug was not reported as being used at higher than recommended dosage in the trials.
“Anti-TNFa drugs such as infliximab, adalimumab and etanercept all appear to be effective in the treatment of RA” said Alonso-Ruiz. “Performing comparisons of new drugs is vital for measuring safety/efficacy relationships and monitoring adverse side-effects”
Media Contact
All latest news from the category: Life Sciences and Chemistry
Articles and reports from the Life Sciences and chemistry area deal with applied and basic research into modern biology, chemistry and human medicine.
Valuable information can be found on a range of life sciences fields including bacteriology, biochemistry, bionics, bioinformatics, biophysics, biotechnology, genetics, geobotany, human biology, marine biology, microbiology, molecular biology, cellular biology, zoology, bioinorganic chemistry, microchemistry and environmental chemistry.
Newest articles
Lighting up the future
New multidisciplinary research from the University of St Andrews could lead to more efficient televisions, computer screens and lighting. Researchers at the Organic Semiconductor Centre in the School of Physics and…
Researchers crack sugarcane’s complex genetic code
Sweet success: Scientists created a highly accurate reference genome for one of the most important modern crops and found a rare example of how genes confer disease resistance in plants….
Evolution of the most powerful ocean current on Earth
The Antarctic Circumpolar Current plays an important part in global overturning circulation, the exchange of heat and CO2 between the ocean and atmosphere, and the stability of Antarctica’s ice sheets….